Online inquiry

IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13074MR)

This product GTTS-WQ13074MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MADCAM1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_130760.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8174
UniProt ID Q13477
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13074MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10251MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ11665MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ11394MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ15361MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ13753MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ9253MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ5162MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ8494MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA hu1124
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW